Clinical Utility of Biocept's Liquid Biopsy Platform Demonstrated in Study Results Presented at the 2016 San Antonio Breast Cancer Symposium
The poster entitled, "Using the Target Selector™ platform to evaluate biomarker alterations in circulating tumor cells isolated from patients with metastatic breast cancer," was presented by
- 84% concordance for ER expression
- 93% concordance for HER2 amplification
- 79% concordance for FGFR1 amplification
The capability of
"The identification of circulating tumor cells in nearly all patients in this study and the high concordance between
"These study results demonstrate that our non-invasive assay platform can address important medical needs in the management of metastatic breast cancer, namely the ability to establish biomarker status when tissue biopsy is challenging or not possible, as well as providing the ability to detect actionable alterations in real-time as metastatic disease progresses," said
"We are proud to present these data from our clinical collaboration with SCRI, which we announced in mid-2015," added
About the San Antonio Breast Cancer Symposium
The 2016 San Antonio Breast Cancer Symposium is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis and therapy of breast cancer and premalignant breast disease to an international audience of physicians and researchers. The symposium is directed primarily toward academic and private physicians and researchers involved in breast cancer in medical, surgical, gynecologic and radiation oncology, as well as other appropriate health care professionals. Approximately 7,500 attendees from more than 90 countries are expected to have attended the 2016 symposium.
About Sarah Cannon Research Institute
Sarah Cannon Research Institute (SCRI) is a global strategic research organization focusing on advancing therapies for patients. It is one of the world's leading clinical research programs, conducting community-based clinical trials in oncology and cardiology through affiliations with a network of more than 1,000 physicians in the United States and United Kingdom. Additionally, SCRI offers management, regulatory, and other research support services for drug development and industry sponsors and strategic investigator sites.
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to our ability to improve the management of cancer patients and improve treatment outcomes, the ability of our platform to serve as a prognostic indicator and detect changes in tumor phenotypes, and our ability to increase physician adoption of our assays, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our Securities and Exchange Commission (SEC) filings. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC, which can be accessed over the Internet at the SEC's website located at www.sec.gov.
Logo: http://photos.prnewswire.com/prnh/20151013/276540LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/clinical-utility-of-biocepts-liquid-biopsy-platform-demonstrated-in-study-results-presented-at-the-2016-san-antonio-breast-cancer-symposium-300374933.html
SOURCE
News Provided by Acquire Media